Key facts
- This page summarizes Eric Dobmeier's Form 4 filing for CHINOOK THERAPEUTICS, INC..
- 8 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 01 Feb 2023, 19:32.
Eric Dobmeier - 30 Jan 2023 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC.
- Reporting relationship
- President, CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 30 Jan 2023
- Net transaction value
- -$792,869
- SEC form
- 4
- Accepted by SEC
- 01 Feb 2023, 19:32:14 UTC
- Prior SEC filing
- 15 Dec 2022
- Next SEC filing
- 02 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kirk Schumacher, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Dobmeier filed Form 4 for CHINOOK THERAPEUTICS, INC. on 01 Feb 2023.
Change
- Previous filing in this sequence was filed on 15 Dec 2022.
- Current net transaction value: -$792,869.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KDNY
transaction
Common Stock
Options Exercise
- Transaction value
- $10,500
- Shares
- +25,000
- Change %
- +9.2%
- Price
- $0.4200*
- Shares after
- 296,676
- Date
- 30 Jan 2023
- Ownership
- Direct
KDNY
transaction
Common Stock
Sale
- Transaction value
- $613,612
- Shares
- -25,000
- Change %
- -8.4%
- Price
- $24.54
- Shares after
- 271,676
- Date
- 30 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F2
KDNY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +24,999
- Change %
- +9.2%
- Price
- Shares after
- 296,675
- Date
- 31 Jan 2023
- Ownership
- Direct
- Footnotes
- F3
KDNY
transaction
Common Stock
Sale
- Transaction value
- $189,757
- Shares
- -7,688
- Change %
- -2.6%
- Price
- $24.68
- Shares after
- 288,987
- Date
- 31 Jan 2023
- Ownership
- Direct
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KDNY
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -25,000
- Change %
- -6.9%
- Price
- $0.000000
- Shares after
- 338,555
- Date
- 30 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $0.4200
- Footnotes
- F5
KDNY
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +255,150
- Change %
- Price
- $0.000000
- Shares after
- 255,150
- Date
- 31 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 255,150
- Exercise price
- $25.27
- Footnotes
- F6
KDNY
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +64,050
- Change %
- Price
- $0.000000
- Shares after
- 64,050
- Date
- 31 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 64,050
- Exercise price
- Footnotes
- F7, F8
KDNY
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -24,999
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 50,001
- Date
- 31 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,999
- Exercise price
- Footnotes
- F7, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.27 to $24.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
Footnote F3
Restricted stock units (RSUs) convert into common stock on a one-for-one basis.
Footnote F4
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Footnote F5
The stock option vested as to 25% of the total shares monthly on March 6, 2021, and thereafter vests as to 1/48 of the total shares until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
Footnote F6
The stock option vests as to 25% of the total shares on January 31, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Footnote F7
Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
Footnote F8
The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2024, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.
Footnote F9
The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.